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Abstract— Introduction: This study aimed to 
investigate the relationship between serum 
adiponectin and metabolic syndrome in adults living 
in rural Malaysia. 
Methods: A total of 299 Malay adults (men=124; 
women = 175) with a mean age 48.8 (11.7) years 
were recruited. Measurements for waist 
circumference and blood pressure were taken before 
drawing an overnight fasting blood samples. 
Biochemical tests for triglycerides, HDL cholesterol, 
glucose and serum adiponectin concentration were 
measured. 
Results: Our results show that the adiponectin level 
in the subjects with metabolic syndrome was 
significantly lower than those without metabolic 
syndrome (p < 0.05). Among the metabolic 
syndrome risk factors, adiponectin level was 
significantly associated with hypertriglyceridemia 
and reduced HDL cholesterol (p < 0.001). 
Conclusion: The outcome from this study which 
highlights the association of hypoadiponectinemia 
with risk factors of metabolic syndrome in Malay 
adults, suggests that the reduced level of adiponectin 
may play a pivotal role in the development of 
metabolic syndrome in this ethnic group.  
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INTRODUCTION 
Metabolic syndrome is an emerging public health 
concern worldwide. The risk factors of metabolic 
syndrome are central obesity, hypertriglyceridaemia, 
reduced high-density lipoprotein cholesterol (HDL 
cholesterol), hypertension, and hyperglycemia.1 
Based on the International Diabetes Federation (IDF) 
definition, the presence of central obesity with any 
two of the other risk factors is qualified for the 
diagnosis of metabolic syndrome.2  
A comprehensive overview on metabolic 
syndrome pandemic in the America, Europe and 
India indicates that more than 20% of the adult 
populations have metabolic syndrome.1 Several 
South East Asian countries such as Indonesia, 
Singapore and Thailand are actively involved in 
evaluating the metabolic syndrome.3-7 There is 
growing interest in assessing whether metabolic 
syndrome is a health threat in our population. This is 
based on the accumulating reports documenting the 
occurrence of metabolic syndrome in Malaysia in 
various locations and sociodemographic 
background.8-11 Since the metabolic syndrome 
pandemic is observed in diverse population therefore 
there is a pressing need to investigate the mechanism 
underlying metabolic syndrome as well as searching 
for robust and sensitive biomarkers to serve as a 
diagnostic tool for early detection of metabolic 
syndrome.  
The underlying mechanisms for development 
of metabolic syndrome remain plausible. The 
accumulated evidence suggests that the reduced 
adiponectin concentration (hypoadiponectinemia) 
plays pathophysiologic role of metabolic syndrome. 
The inverse correlation between visceral adiposity 
and adiponectin concentration suggests that 
hypoadiponectinemia is unequivocally associated 
with central obesity, a principal feature for metabolic 
syndrome.12-14  
Adiponectin, a type of adipose-specific 
serum protein can be found extensively in serum 
ranging from 1.9–17.0 μg/ml.15 It is expressed 
inversely to total fat, and acted not only as anti-
diabetic but also as anti-inflammatory and 
anti-atherogenic agent.16 In the last few years, a 
growing body of evidence suggests that adiponectin 
is a potential biomarker for the metabolic syndrome 
and its risk factors. The present study was designed 
to examine the association between serum 
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adiponectin level and metabolic syndrome or risk 
factors in the Malay adults in Malaysia. 
METHODS 
Study subjects 
This was a cross-sectional study involving a total of 
299 Malay adults recruited from October 2008 to 
August 2009. This study was approved by the 
Human Research Ethics Committee of Universiti 
Sains Malaysia (USMKK/PPP/JEPeM [205.4.(1.3)]. 
Written informed consent was obtained from all of 
the subjects. Each subject was interviewed using a 
structured questionnaire on demographic 
characteristics such as age, sex, and personal medical 
history. A qualified nutritionist measured height, 
weight and waist circumference using a portable 
bodymeter (Seca 206, Germany), body composition 
monitor (Tanita BC545, Japan) and non-elastic 
measurement tape (Seca 201, Japan). After 15 
minutes of rest, blood pressure was measured twice 
by a trained laboratory technician using an automatic 
blood pressure monitor (Omron SEM-1, Japan). The 




Peripheral venous blood samples were collected after 
an overnight fasting. Metabolic syndrome 
biomarkers such as fasting blood glucose, 
triglycerides and high-density lipoprotein cholesterol 
were assessed with commercially available reagents 
(Randox, UK) by using Vitalab Selectra E chemistry 
analyzer (Vitalab, Netherlands). Serum adiponectin 
concentration was determined by using the Human 
Adiponectin Enzyme-Linked Immunosorbent Assay 
(ELISA) kit (Chemicon, USA).  
 
Definition of Metabolic Syndrome 
The following risk factors and criteria were used: 
central obesity (waist circumference; men ≥ 90 cm, 
women ≥ 80 cm) plus any two of the following: (1) 
raised triglycerides (> 1.7 mmol/L (150 mg/dL) or 
specific treatment for this lipid abnormality); (2) 
reduced HDL-cholesterol (men <1.03 mmol/L (40 
mg/dL) or women <1.29 mmol/L (50 mg/dL) or 
specific treatment for this lipid abnormality); (3) 
raised blood pressure (≥ 130/85 mm Hg or treatment 
of previously diagnosed hypertension); (4) raised 
fasting plasma glucose (≥ 5.6 mmol/L (100 mg/dL) 
or previously diagnosed type 2 diabetes). 
 
Statistical analyses 
Subjects with missing information in socioeconomic, 
anthropometric measurements and blood analyses 
were excluded from statistical analyses. Each 
variable was examined for normality of frequency 
distribution based on the histogram. Normally 
distributed data were expressed as mean (standard 
deviation or SD) and skewed data were expressed as 
median (Interquartile Range or IqR). The Mann-
Whitney U test was conducted to study association 
of adiponectin concentration and metabolic 
syndrome or risk factors. The two-way ANOVA 
analysis of variance was applied to explore the mean 
differences of adiponectin concentration on status of 
metabolic syndrome or risk factors. Although this 
test requires the dependant variables to be normally 
distributed, however it is robust against violations of 
the assumption of the normal distribution (17). A 2-
tailed value of p < 0.05 was considered significant. 
All statistical analyses were performed using the 
Predictive Analytics Software (PASW Statistics 
18.0) (SPSS Inc., Chicago, IL, USA). 
RESULTS 
A total of 299 Malay adults mean (Mean age ± SD: 
48.8 ± 11.7) of which 124 were men (49.8 ± 11.7) 
and 175 were women (48.6 ± 11.8) were recruited in 
this study. Clinical characteristics of metabolic 
syndrome among the subjects i.e the mean (SD) for 
waist circumference, systolic and diastolic blood 
pressures, glucose, triglycerides and HDL 
cholesterol, and median (IqR) for adiponectin 
concentration are presented in Table 1. 
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The association of adiponectin level with metabolic 
syndrome were examined using Mann-Whitney U 
test (Figure 1). The median (IqR) of adiponectin 
concentration among those with and without 
metabolic syndrome were 5.8 (3.7) μg/ml and 7.2 
(6.8) μg/ml, respectively. The adiponectin level 
among those with metabolic syndrome was 
significantly lower than those without metabolic 
syndrome (p = 0.004). 
The association of adiponectin concentration with 
the individual metabolic syndrome risk factors is 
presented in Figure 2 and Table 2.  
Subjects with high level of triglyceride (5.2 
μg/ml) had significantly lower level of serum 
adiponectin than subjects with lower triglycerides 
(7.7 μg/ml) (p < 0.001).  
Similarly, subjects with reduced HDL cholesterol 
(5.8 μg/ml) had significantly lower concentration of 
serum adiponectin concentration than subjects with 
elevated HDL cholesterol (8.1 μg/ml) (p < 0.001). 
 
DISCUSSION 
The total serum adiponectin level observed in the 
Malay population is comparable with a study 
conducted among the Japanese, but lower than in  
other populations (Table 3). The adiponectin 
concentration reported among the Malays with 
metabolic syndrome was significantly lower than 
those without metabolic syndrome; this finding is in 
agreement with other reported studies.18,19 
The Malay subjects with 
hypertriglyceridemia or reduced HDL cholesterol 
had significantly lower concentration of serum 
adiponectin concentration than those without them, 
respectively. The result is in accordance with 
previous reports from various population such as 
Caucasian24 and Japanese25 and large-scale 
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nationwide studies such as Rancho Bernardo Study26 
and KORA Survey 2000.27 Although the exact 
crosslink between adiponectin and lipid metabolism 
remains unknown, it was proposed that adiponectin 
acts with HDL cholesterol in reverse cholesterol 
transport and involved in hepatic lipase activity.28 
The finding from this study whereby 
hypoadiponectinemia is significantly associated with 
hypertriglyceridemia and reduced HDL cholesterol, 
suggests that an increased in adiponectin level could 
have protective effect via promoting HDL 
cholesterol and reducing the triglycerides. 
We found no significant association between 
adiponectin with central obesity which appears to be 
in contradiction with the previous reports.24,29 Such 
conflicting finding could be attributed by the 
adiponectin multimeric forms. Serum adiponectin 
exists as a trimer; low molecular weight (LMW) 
hexamers, medium molecular weight (MMW) and 
high molecular weight (HMW) multimerics. The 
HMW is thought to be the active form of the 
adiponectin, and is implicated in the progression of 
metabolic syndrome.30,31 Lara-Castro and the group 
reported that the reduced concentration of HMW 
adiponectin was associated with measures of central 
fat distribution, rather than the total adiponectin that 
were commonly investigated by many researchers.32 
As findings from this study found no significant 
association between adiponectin and central obesity, 
it was proposed that adiponectin, specifically the 
total adiponectin measured during the course of the 
study, was not responsible for the association with 
central obesity in Malay population. Perhaps future 
investigation of HMW would provide more 
conclusive perspective. 
Circulating adiponectin levels have been 
studied for their role in different ethnic groups which 
suggests that adipose tissue mass or distribution may 
be attributed by ethnic variation.33 Since the present 
study displayed no significant association between 
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adiponectin and central obesity, further studies on 
the influence of Malay ethnic factor perhaps could 
explain the discrepancy.  
The adiponectin concentration found in 
Malay subjects with hypertension was similar to 
those without hypertension. To our knowledge there 
are limited studies associating adiponectin and 
hypertension as compared to other risk factors. 
Besides, a number of studies purposely examined 
hypoadiponectinemia and hypertension in selected 
patients with other abnormalities for example in 
patients with essential hypertension; a form of high 
blood pressure with no identifiable cause or among 
obese participant.34,35  
The association of hypoadiponectinemia and 
type 2 diabetes has been demonstrated as early as 
2000.36 Adiponectin is regarded as an insulin 
sensitizer that enhances insulin sensitivity by 
increasing fatty acid oxidation and inhibiting the 
hepatic glucose production.37 Several studies carried 
out in diverse population show that diabetic subjects 
experience hypoadiponectinemia as compared to 
their nondiabetic counterparts.38-40 We found no 
significant difference of the adiponectin level 
between hyperglycemic and non-hyperglycemic in 
our studied subjects. Increasing the sample size and 
expanding this cross-sectional study to a cohort study 
with longer follow-up may fill in the gaps. 
Here we report the association of adiponectin 
levels in the Malay ethnics in Malaysia and its 
association with metabolic syndrome risk factors. 
The study population was selected from a rural area, 
thus the result may not be generalised to Malays 
living in urban Malaysia due to differences in 
socioeconomic status. A nationwide multicentre 
study involving not only Malay ethnics but also 
Indian Malaysian and Chinese Malaysian may 
provide perspective into the role of adiponectin in the 
development of metabolic syndrome in Malaysian. 
Studies have suggested that adiponectin can be a 
promising therapeutic agent for metabolic syndrome 
and its risk factors. Increasing circulating 
adiponectin concentration or enhancing adiponectin 
signalling through its receptors could promisingly 
tackle the root that cause the metabolic syndrome.41 
Although the claims excited many researchers, future 
investigations taking the ethnic differences into 
account, are required to support the matter. 
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